PATENT CLAIM ANALYSIS

Application Number: 15761676
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-12
Patent Classification: ["424", "450000"]

Abstract:
The present invention provides improved stable liposomal formulations and method of preparation thereof. The liposomal formulations include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and a taxane, wherein the taxane is docetaxel or a derivative thereof. The liposomal formulations have improved stability and extended shelf-life. The present invention also provides pharmaceutical compositions comprising a liposomal formulation for the treatment of cancer.

Claim (Index 2):
The liposomal formulation of  claim 1 , wherein the therapeutic agent is selected from the group consisting of amphotericin B, doxorubicin, bupivacaine camptothecin, carfilzomib, daunorubicin, vincristine, cisplatin, oxaloplatin, irinotecan, topotecan, annamycin, cytarabine, paclitaxel, sunitinib, imatinib, lapatinib, mitomycin C, epirubicin, pirarubicin, rubidomycin, carcinomycin, N-acetyladriamycin, rubidazone, 5-imido daunomycin, N-acetyl daunomycin, daunory line, mitoxanthrone, morphine, camptothecin, 9-aminocamptothecin, 7-ethylcamptothecin, 7-Ethyl-10-hydroxy-camptothecin, 10-hydroxycamptothecin, 9-nitrocamptothecin, 10, 11-methylenedioxycamptothecin, 9-amino-10, 11-methylenedioxycamptothecin, 9-chloro-10, 11-methylenedioxycamptothecin, irinotecan, lurtotecan, silatecan, (7-(4-methylpiperazinomethylene)-10,11-ethylenedioxy-20(S)-camptothecin, 7-(4-methylpiperazinomethylene)-10, II-methylenedioxy-20(S)-camptothecin, 7-(2-N-isopropylamino)ethyl)-(20S)-camptothecin, CKD-602, vincristine, vinblastine, vinorelbine, vinflunine, vinpocetine, vindesine, verteporfin, ellipticine, 6-3-aminopropyl-ellipticine, 2-diethylaminoethyl-ellipticinium, datelliptium, retelliptine, paclitaxel, docetaxel, diclofenac, bupivacaine, 17-Dimethylaminoethylamino-17-demethoxygeldanamycin, cetirizine, fexofenadine, primidone and other catecholamines, epinephrine, (S)-2-(2,4-dihydroxyphenyl)-4,5-dihydro-4-methyl-4-thiazolecarboxylic acid (deferitrin), (S)-4,5-dihydro-2-(3-hydroxy-2-pyridinyl)-4-methyl-4-thiazolecarboxylic acid (desferrithiocin), (S)-4,5-dihydro-2-[2-hydroxy-4-(3,6,9,12-tetraoxamidecyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid, (S)-4,5-dihydro-2-[2-hydroxy-4-(3,6-dioxaheptyloxy)phenyl]-4-methyl-4-thiazolecarboxylic acid, ethyl (S)-4,5-dihydro-2-[2-hydroxy-4-(3,6-dioxaheptyloxy)phenyl]-4-methyl-4-thiazolecarboxylate, (S)-4,5-dihydro-2-[2-hydroxy-3-(3,6,9-trioxadecyloxy)]-4-methyl-4-thiazolecarboxylic acid and desazadesferrithiocin, including salts, prodrugs and derivatives thereof.

Metadata:
- Claim Count in Document: 45.0
- Percentile: 90.0
- Lexical Diversity: 1.69048
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15407512', '15253307', '14255637', '15301570', '14208297']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8036697045618744
- 35 USC 102 Novelty (BERT): 0.5234512742752282
- Combined Prediction Score: 0.7756478615332097
- Mean Citation Score: 330.527132
- Max Citation Score: 337.90787
- Similarity Product: 228.99540454776343

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test